Gala vs Hers: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hers beats Gala overall, scoring 7.3/10 vs 7.2/10. Gala is more affordable at $149/mo vs $199/mo. Choose Gala for tirzepatide-first patients who want a low-cost compounded pa. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.
A side-by-side comparison of Gala and Hers covering pricing, scores, medication types, insurance, and more to help you decide.
Gala
#40 of 49Telehealth platform focused on compounded tirzepatide — both microdose and full-dose tiers — alongside a brand-name semaglutide (Ozempic) path and a 'coming soon' Wegovy pill. Operated by AI Coaching, Inc. (Wilmington, DE), backed by OpenLoop-affiliated medical groups (a recognized US telehealth backend) and LegitScript verified. Differentiator: a dedicated 'Gala GLP-1 Tracker' iOS + Android app for in-treatment dosing, weight, and side-effect logging.
Visit GalaHers
#35 of 49The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.
Visit Hers| Feature | Gala | Hers |
|---|---|---|
| Our Score | 7.2/10 | 7.3/10 |
| Starting Price | $149/mo | $199/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated iOS + Android tracker app for daily progress logging | Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand |
| Ranking | #40 | #35 |
Pros & Cons Compared
Gala
Pros
- +Microdose compounded tirzepatide at $149/mo — the cheapest microdose tirz on a tracked telehealth platform; full-dose compounded tirzepatide at $179/mo (yearly plan) or $199/mo (3-month plan)
- +Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android — first-party in-treatment logging is uncommon among compounded-only platforms
- +OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack
- +All 50 states, free shipping, no insurance required, 24/7 patient support claimed
Cons
- −Brand-name Ozempic pricing ($1,299/mo) is materially above market — NovoCare direct pricing for Wegovy is $349/mo, Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership
- −Tirzepatide-only on the compounded side — compounded semaglutide is NOT offered, narrower medication menu than peers like Maximus, Ro, or Henry Meds
- −Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness — verify your specific dose and batch with each refill
- −Initial consultation typically a sync video visit, but ongoing follow-ups and questions are chat-based (no scheduled ongoing video access) — and no published labs, no named medical director, no specialty obesity oversight
- −Restrictive refund policy — Gala's published terms state 'IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES' with a narrow exception for provider-initiated medical disqualification. No money-back guarantee. Read the published policy at galaglp1.com/refund-policy before enrolling on a commitment plan
- −Newer brand under AI Coaching, Inc. (founded 2024 per LinkedIn) — limited public company history; founders, founding year, and named medical director not publicly disclosed on galaglp1.com itself
Hers
Pros
- +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services
Cons
- −Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
- −Generic support experience — large patient volume means less personalized attention
- −Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
- −Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value
Our Verdict
Hers edges out Gala with a score of 7.3/10 vs 7.2/10. If budget is your priority, Gala starts at $149/mo compared to Hers's $199/mo. Choose Gala if you want: tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated ios + android tracker app for daily progress logging. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.
Still undecided? Editor's #1 Overall Pick
Embody
$299/mo · 7.3/10 · Compounded
If neither Gala nor Hers feels like the right fit, our overall #1 pick across all 49 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.
Read Full Reviews
Related comparisons
Other matchups readers comparing Gala or Hers tend to look at next.
- Gala vs TMates$158/mo
- Gala vs FeelGood$149/mo
- Gala vs Oak Longevity$130/mo
- Hers vs TrimRx$199/mo
- Hers vs Enhance MD$212/mo
- Hers vs Sesame Care$99/mo